HGH (Somatropin)
The original recombinant anabolic peptide drug: a 191-amino-acid copy of human growth hormone, FDA-approved for decades in true deficiency and heavily criminalized off-label.
HGH (somatropin) is recombinant human growth hormone, a 191-amino-acid peptide identical in sequence to the GH produced by the pituitary gland. First synthesized by Genentech in 1981 and FDA-approved as Protropin in 1985, it is now sold under 11+ brand names for pediatric growth failure, adult GH deficiency, Turner syndrome, HIV wasting, and short bowel syndrome. In genuine deficiency the evidence is overwhelming; in healthy adults seeking anti-aging or performance effects, meta-analyses find only modest body-composition shifts alongside common side effects, and off-label distribution is a federal felony in the US.
Class
Recombinant human growth hormone (191-amino-acid somatropin)
Half-life
~2-4 hours (rapid-acting somatropin); ~1 week (long-acting weekly formulations)
Routes
Subcutaneous injection
Category
Growth Hormone & Performance
Researched benefits
What it's studied for
Treats pediatric growth failure
FDA-approved since 1985 across multiple pivotal trials for children with GH deficiency and short-stature conditions. This is the original, uncontroversial use case with decades of outcome data.
Treats adult GH deficiency
FDA-approved and well-established for pituitary disease and surgical or radiation-induced deficiency. The 2022 KIMS registry strengthens the long-term safety case in true deficiency.
Increases lean mass and reduces fat
At supraphysiologic doses HGH raises lean body mass and lowers fat mass via IGF-1-mediated anabolism and lipolysis. However, strength gains are debated and multiple meta-analyses find minimal functional improvement.
Supports tissue repair and metabolism
By binding the GH receptor on nearly every tissue and driving hepatic IGF-1 output, HGH promotes bone turnover, protein synthesis, and metabolic activity.
Reverses HIV-associated wasting
Serostim is FDA-approved for HIV-associated wasting, where the evidence for lean-mass restoration is well documented.
Weekly dosing options for patients
Long-acting once-weekly formulations (Sogroya 2020, Skytrofa 2021, Ngenla/somatrogon 2023) are a genuine win for patients who need GH but do not want a daily injection.
Mechanism
How it works
HGH binds the growth hormone receptor on nearly every tissue in the body. The principal downstream signal is the liver's production of insulin-like growth factor 1 (IGF-1), which drives anabolism, lipolysis, lean-mass accrual, and bone turnover.
Recombinant somatropin carries the identical 191-amino-acid sequence to endogenous human GH, but its pharmacokinetics differ: natural GH is secreted in pulses, whereas injected somatropin is delivered as a bolus. Rapid-acting somatropin has a half-life of roughly 2-4 hours, while long-acting variants extend to about a week.
In genuine GH deficiency the effect is clean and well-documented, restoring normal growth and body composition. In healthy adults at supraphysiologic doses, meta-analyses find only modest body-composition shifts of unclear functional benefit, because chronically elevated IGF-1 also carries acromegaly-like and cancer-risk concerns.
Oral and over-the-counter HGH products do not work: the peptide is destroyed by digestion, and sprays, pills, and 'releasers' do not reliably deliver GH — many contain none at all.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Clinical (approved indications)
- Dose
- Individualized to indication, body weight, formulation, and IGF-1 response
- Frequency
- Once daily
- Timing
- Typically evening, subcutaneous
- Duration
- Long-term per clinical guidance
- Route
- Subcutaneous injection
Standard rapid-acting somatropin is dosed daily and titrated to IGF-1 levels and clinical response under endocrinology supervision.
Long-acting formulations
- Dose
- Individualized per product label
- Frequency
- Once weekly
- Timing
- Subcutaneous, same day each week
- Duration
- Long-term per clinical guidance
- Route
- Subcutaneous injection
Sogroya, Skytrofa, and Ngenla (somatrogon) are weekly formulations for patients who need GH but want to avoid daily injections.
- FDA-approved dosing depends on indication, body weight, formulation, and IGF-1 response, and belongs in a conversation with a clinician.
- Oral HGH is destroyed by digestion; OTC sprays, pills, and releasers do not reliably deliver GH.
- Off-label anti-aging and performance dosing sits outside the approved framework and carries a stricter US legal risk profile than most peptides, including felony distribution liability under 21 U.S.C. § 333(e).
Evidence
Research & clinical studies (3)
Effects of human growth hormone in men over 60 years old
Rudman's landmark trial of twelve men over 60 reported improved body composition over six months, but the authors explicitly did not claim anti-aging benefit — a finding widely misinterpreted to launch the anti-aging industry.
Systematic review: the safety and efficacy of growth hormone in the healthy elderly
Liu et al. concluded that GH in healthy older adults produces only small body-composition changes of unclear functional value, with common side effects including carpal tunnel syndrome, edema, and glucose intolerance.
KIMS (Pfizer International Metabolic Database) long-term safety registry
The 2022 KIMS registry strengthens the long-term safety case for GH replacement in patients with true GH deficiency.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Active malignancy or cancer-risk pathways (sustained IGF-1 elevation)
- Off-label distribution in the US is a federal felony
- Prohibited in competitive sport (WADA S2)
Common side effects include fluid retention, joint pain, carpal tunnel syndrome, and insulin resistance. Long-term supraphysiologic use carries acromegaly-like risks including organ growth and potential cancer-risk elevation consistent with chronically elevated IGF-1. Long-term safety data in healthy adults is limited and concerning.
FAQ
HGH (Somatropin) — common questions
What is HGH?
Human growth hormone (somatropin) is a recombinant 191-amino-acid peptide hormone identical to the GH produced by the pituitary gland. Multiple branded formulations are FDA-approved for specific deficiency and growth-related indications.
What does HGH do?
HGH stimulates linear growth in children with GH deficiency, increases lean body mass, reduces fat mass, and supports tissue repair and metabolism via IGF-1-mediated signaling. Clinical trials in approved indications show substantial efficacy; anti-aging claims in healthy adults have significantly weaker evidence.
How is HGH typically administered?
HGH is given as a subcutaneous injection, usually daily for standard somatropin or once weekly for long-acting formulations. FDA-approved dosing depends on indication, body weight, formulation, and IGF-1 response.
What are the side effects of HGH?
Common side effects include fluid retention, joint pain, carpal tunnel syndrome, and insulin resistance. Long-term supraphysiologic use carries acromegaly-like risks including organ growth and potential cancer-risk elevation from sustained IGF-1 elevation.
Is HGH FDA approved?
Yes. Multiple somatropin formulations (Humatrope, Genotropin, Norditropin, Omnitrope, Saizen, and others) are FDA-approved for indications including pediatric and adult GH deficiency, Turner syndrome, short-stature conditions, and HIV wasting. General anti-aging use is not FDA-approved.
Does HGH reverse aging?
No controlled trial supports the anti-aging case in healthy adults. Rudman's 1990 NEJM paper — which started the industry — never claimed anti-aging, and 35 years later the marketing is still ahead of the evidence.
Do over-the-counter HGH products work?
No. Oral HGH is destroyed by digestion, and OTC sprays, pills, and releasers do not reliably deliver GH — many contain no HGH at all.
Is HGH legal?
For approved medical indications, yes, by prescription. Off-label distribution for anti-aging or performance is a federal felony in the US under 21 U.S.C. § 333(e), and HGH is banned in sport as a WADA S2 substance.
